158 related articles for article (PubMed ID: 11774254)
1. Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues.
Miyoshi Y; Ando A; Takamura Y; Taguchi T; Tamaki Y; Noguchi S
Int J Cancer; 2002 Jan; 97(1):129-32. PubMed ID: 11774254
[TBL] [Abstract][Full Text] [Related]
2. Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers.
Miyoshi Y; Taguchi T; Kim SJ; Tamaki Y; Noguchi S
Breast Cancer; 2005; 12(1):11-5. PubMed ID: 15657517
[TBL] [Abstract][Full Text] [Related]
3. Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer.
Egawa C; Miyoshi Y; Takamura Y; Taguchi T; Tamaki Y; Noguchi S
Int J Cancer; 2001 Jul; 95(4):255-9. PubMed ID: 11400119
[TBL] [Abstract][Full Text] [Related]
4. Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers.
Takamura Y; Kobayashi H; Taguchi T; Motomura K; Inaji H; Noguchi S
Int J Cancer; 2002 Mar; 98(3):450-5. PubMed ID: 11920599
[TBL] [Abstract][Full Text] [Related]
5. CYP3A4 expression to predict treatment response to docetaxel for metastasis and recurrence of primary breast cancer.
Sakurai K; Enomoto K; Matsuo S; Amano S; Shiono M
Surg Today; 2011 May; 41(5):674-9. PubMed ID: 21533940
[TBL] [Abstract][Full Text] [Related]
6. Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers.
Hasegawa S; Miyoshi Y; Egawa C; Ishitobi M; Taguchi T; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2003 Aug; 9(8):2992-7. PubMed ID: 12912947
[TBL] [Abstract][Full Text] [Related]
7. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
Hirth J; Watkins PB; Strawderman M; Schott A; Bruno R; Baker LH
Clin Cancer Res; 2000 Apr; 6(4):1255-8. PubMed ID: 10778948
[TBL] [Abstract][Full Text] [Related]
8. Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer.
Fujitaka K; Oguri T; Isobe T; Fujiwara Y; Kohno N
Cancer Chemother Pharmacol; 2001 Jul; 48(1):42-6. PubMed ID: 11488523
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers.
Miyoshi Y; Kim SJ; Akazawa K; Kamigaki S; Ueda S; Yanagisawa T; Inoue T; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2004 Dec; 10(24):8163-9. PubMed ID: 15623590
[TBL] [Abstract][Full Text] [Related]
10. Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers.
Takahashi Y; Miyoshi Y; Morimoto K; Taguchi T; Tamaki Y; Noguchi S
J Cancer Res Clin Oncol; 2007 Aug; 133(8):501-9. PubMed ID: 17297610
[TBL] [Abstract][Full Text] [Related]
11. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer.
Kim SJ; Miyoshi Y; Taguchi T; Tamaki Y; Nakamura H; Yodoi J; Kato K; Noguchi S
Clin Cancer Res; 2005 Dec; 11(23):8425-30. PubMed ID: 16322305
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.
Smith IC; Heys SD; Hutcheon AW; Miller ID; Payne S; Gilbert FJ; Ah-See AK; Eremin O; Walker LG; Sarkar TK; Eggleton SP; Ogston KN
J Clin Oncol; 2002 Mar; 20(6):1456-66. PubMed ID: 11896092
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.
Chang JC; Wooten EC; Tsimelzon A; Hilsenbeck SG; Gutierrez MC; Elledge R; Mohsin S; Osborne CK; Chamness GC; Allred DC; O'Connell P
Lancet; 2003 Aug; 362(9381):362-9. PubMed ID: 12907009
[TBL] [Abstract][Full Text] [Related]
15. 70-Gene classifier for differentiation between paclitaxel- and docetaxel-sensitive breast cancers.
Naoi Y; Tanei T; Kishi K; Tsunashima R; Tominaga N; Baba Y; Nakayama T; Shimazu K; Kim SJ; Tamaki Y; Noguchi S
Cancer Lett; 2012 Jan; 314(2):206-12. PubMed ID: 22018777
[TBL] [Abstract][Full Text] [Related]
16. Biotransformation of taxoids by human cytochromes P450: structure-activity relationship.
Monsarrat B; Royer I; Wright M; Cresteil T
Bull Cancer; 1997 Feb; 84(2):125-33. PubMed ID: 9180834
[TBL] [Abstract][Full Text] [Related]
17. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol.
Yamamoto N; Tamura T; Kamiya Y; Sekine I; Kunitoh H; Saijo N
J Clin Oncol; 2000 Jun; 18(11):2301-8. PubMed ID: 10829051
[TBL] [Abstract][Full Text] [Related]
18. Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes.
Nallani SC; Goodwin B; Buckley AR; Buckley DJ; Desai PB
Cancer Chemother Pharmacol; 2004 Sep; 54(3):219-29. PubMed ID: 15175893
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients.
Kurosumi M; Tabei T; Suemasu K; Inoue K; Kusawake T; Sugamata N; Higashi Y
Oncol Rep; 2000; 7(5):945-8. PubMed ID: 10948319
[TBL] [Abstract][Full Text] [Related]
20. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship.
Cresteil T; Monsarrat B; Dubois J; Sonnier M; Alvinerie P; Gueritte F
Drug Metab Dispos; 2002 Apr; 30(4):438-45. PubMed ID: 11901098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
